Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

The latest trading session saw Novavax (NVAX) ending at $12.80, denoting a -0.85% adjustment from its last day's close. The stock trailed the S&P 500, which registered a daily gain of 0.28%. Meanwhile ...

Health Canada said Thursday it has authorized Novavax's updated COVID-19 vaccine for those aged 12 years and up.

在近期的疫苗市场动态中，诺瓦瓦克斯医药 (Novavax)的疫苗上市引发了广泛关注。该公司的新冠疫苗已在美国获得批准，旨在防止至少12岁以上人群感染新冠，然而，疫苗概念股的表现却显得涨跌不一。这一现象不仅反映了市场对疫苗的信心，也揭示了更为复杂的投资心理。

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

马里兰州盖瑟斯堡 - Novavax, Inc. (NASDAQ:NVAX) 宣布其针对JN.1变种的新型新冠疫苗配方现已在全国范围内的药房供应。Novavax新冠疫苗(佐剂型)(2024-2025配方)目前已在主要连锁药房和数千家独立药房上架,为12岁及以上人群提供了一种蛋白质基疫苗选择。 这种更新版疫苗还可以预防KP.2.3、KP.3、KP.3.1.1和LB.1.1等相关毒株,于2024年8月 ...

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

Health Canada authorized Novavax's updated COVID-19 vaccine that protects against currently circulating variants of the virus ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Supported by world-class markets data from Dow Jones and FactSet, and partnering with Automated Insights, MarketWatch Automation brings you the latest, most pertinent content at record speed and with ...